Amocla

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amocla

Property Description
Active ingredients Amoxicillin and Clavulanic acid
Form Tablets, Oral Suspension, Powder for Injection
Pharmacological class beta-Lactam/beta-Lactamase Inhibitor Combination
Common use Treatment of bacterial infections
Origin Semi-synthetic (derivative of penicillin)

What Type of Medicine is Amocla and How is it Classified?

Amocla is a widely recognized trade name for the prescription medicine officially known by the generic name Co-amoxiclav, which is classified as an anti-infective agent. This drug belongs to the penicillin class of antibiotics and is a semi-synthetic preparation. The drug is clinically recognized for its utility in combating a variety of bacterial pathogens that may exhibit resistance to standard penicillins. Its core purpose is to provide bactericidal action against susceptible bacteria within the body.

Composition: Why Does Amocla Have Two Active Ingredients?

The product is a fixed-dose combination, which is a defining feature of Co-amoxiclav preparations, containing two essential substances: the core antibacterial agent Amoxicillin and the protective component Clavulanic acid. Amoxicillin functions as the primary agent against bacteria, and it is combined with Clavulanic acid specifically to safeguard its action. Clavulanic acid's mechanism prevents certain bacteria from destroying Amoxicillin. The medicine is supplied for oral administration in various forms, including tablets and suspension, as well as in a powder format for intravenous injection.

General Purpose: What is the Benefit of the Amoxicillin/Clavulanic Acid Combination?

The general purpose of this combination is to provide a systemic solution for bacterial infections, particularly those that have developed resistance to Amoxicillin when used alone. Through synergy, the Clavulanic acid functions as a specific beta-lactamase inhibitor, preventing the bacterial enzymes from deactivating the Amoxicillin. This combination is commonly used to treat a wide scope of bacterial infections. The inclusion of Clavulanic acid helps ensure the antibiotic can work against a variety of infections, including those affecting the respiratory tract or skin structures.

What side effects are possible with Amocla?

Possible side effects and safety information

The official safety profile for Amocla (Co-amoxiclavin) details potential adverse reactions based on regulatory classifications, grouping them by frequency and the body system affected. This information is derived solely from government regulatory documents, such as the FDA and EMA.

Frequency-Classified Adverse Reactions

The frequency of possible side effects is formally categorized in regulatory documentation:

  • Very Common (>1/10): Diarrhoea (specifically noted in adults).
  • Common (>1/100 to <1/10): Mucocutaneous candidosis (thrush), Nausea, and Vomiting.
  • Uncommon (>1/1,000 to <1/100): Headache, Dizziness, Indigestion, Skin rash, Urticaria, and elevations in liver enzymes (AST/ALT).

System-Organ-Class Safety Groupings

The most commonly affected body systems noted in official labeling include Gastrointestinal disorders (diarrhoea, vomiting, colitis), Skin and subcutaneous tissue disorders (rash, pruritus), and Hepatobiliary disorders (hepatitis, cholestatic jaundice).

Serious Adverse Reactions and Constraints

The regulatory label documents the potential for rare, serious adverse events. These include life-threatening Severe Hypersensitivity Reactions (such as Anaphylaxis), Severe Cutaneous Adverse Reactions (SCARs), and severe Hepatic Dysfunction. The medicine is strictly contraindicated for individuals with a history of severe immediate hypersensitivity to any penicillin or other beta-lactam agents, or a history of Co-amoxiclav-related hepatic dysfunction.

Population and Time-Related Safety Patterns

Specific safety notes apply to certain populations: Hepatic events are reported to occur predominantly in males and elderly patients. Patients with renal impairment face an increased risk of convulsions. Regarding timing, official documents note that hepatic events may be delayed, appearing several weeks after treatment cessation, while other reactions, like Acute generalised exanthemous pustulosis (AGEP), typically occur at treatment initiation.

Overdose and Emergency Response

The officially documented descriptions of Amocla overdose primarily involve two systems: the gastrointestinal tract and the renal-urinary system. Overdose presentations include common gastrointestinal effects such as diarrhea, stomach pain, nausea, and vomiting. Additionally, neurological signs like sleepiness or more severe manifestations such as seizures (convulsions) have been reported with high drug concentrations.

Overdose is associated with the potential for the Amoxicillin component to cause crystalluria, or the formation of crystals in the urine, which can lead to serious outcomes including acute renal failure. This risk is officially noted to be greater in patients with impaired renal function due to the drug’s reduced clearance.

The regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose. Urgent medical help must be sought if severe or life-threatening symptoms are observed, such as seizures, collapse, or trouble breathing. Treatment is defined as symptomatic and supportive care, aimed at maintaining adequate fluid intake to reduce crystalluria risk. While no specific antidote is known, the regulatory literature notes that the Amoxicillin component can be effectively removed from circulation by hemodialysis.

Therapeutic Uses of Amocla

Amocla (Amoxicillin/Clavulanic acid) is a therapeutic agent commonly used to address bacterial infections that present with symptoms that interfere with daily functioning in scenarios where the infection requires a broad therapeutic approach. The medication is generally applied across domains where symptoms may intensify temporarily, providing support for symptom management during acute episodes. This agent is utilized to help manage conditions characterized by periods of heightened symptoms.

Treating Acute Bacterial Illnesses

The combination is applied across domains where additional symptomatic support is needed. It is commonly used in conditions presenting with acute episodes like community-acquired pneumonia, sinusitis, and acute otitis media, helping to manage symptoms that create noticeable physiological strain, such as fever, cough, and localized pain. The primary benefit supports easing the overall symptom burden and may assist with maintaining comfort during symptomatic periods.

Supporting Complex Symptom Management

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as infections following bite wounds or in more complex cases like pyelonephritis. It is used to address the pronounced symptoms of these conditions marked by increased physiological stress, including severe swelling and localized pain. This usage supports the patient during difficult episodes by helping to address symptoms that create noticeable functional strain, such as swelling and pain.

Quick Fact: Relief for Acute Discomfort
Main Use: Applied in scenarios where additional management of discomfort is required, focusing on acute episodes.
Patient Benefit: Contributes to easing the overall symptom load during periods of heightened physical discomfort.
Symptom Focus: Helps address symptoms related to systemic imbalance and inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile for Amoxicillin and Clavulanate Potassium

Official regulatory information defines specific populations that must not use this medicine or who require restricted use.

Contraindicated Populations

Use is strictly forbidden for individuals who have:

  • A documented history of serious hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) to amoxicillin, clavulanate, or to any other beta-lactam antibacterial drugs (penicillins and cephalosporins).
  • A previous history of cholestatic jaundice or hepatic dysfunction specifically associated with prior treatment using amoxicillin/clavulanate.
  • A diagnosis of infectious mononucleosis (the medicine must be avoided).

Restricted or Conditional Use

Certain conditions require careful consideration, dose adjustment, or close monitoring:

  • Severe Renal Impairment: Patients with a creatinine clearance below 30 mL/min must not use certain extended-release formulations and require mandatory dose adjustments for all other forms.
  • Hepatic Impairment: Use requires caution and periodic monitoring of liver function.
  • Phenylketonuria (PKU): Patients with PKU must not use formulations (such as chewable tablets or certain suspensions) that contain aspartame.

Age and Physiological Status

  • Children: Dosing is weight-based for children under 40 kg, and certain adult-strength formulations are not recommended for this group.
  • Pregnancy and Lactation: Use is conditional. It should only be used during pregnancy if clearly needed, and caution is advised during breastfeeding due to potential effects on the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents specify that the co-administration of Amocla (Amoxicillin/Clavulanic acid) with certain medicinal products results in pharmacokinetic or pharmacodynamic interactions. Co-administration with the uricosuric agent Probenecid is not recommended as this interaction delays the excretion of the Amoxicillin component, resulting in increased and prolonged plasma concentrations. This is classified as a pharmacokinetic interaction based on competitive inhibition of renal tubular secretion.

Documented Pharmacodynamic and Exposure Interactions

Interacting Product Category Official Interaction Statement
Oral Anticoagulants (e.g., Warfarin) Concomitant use may increase the prolongation of prothrombin time (INR), which is associated with an increased risk of bleeding.
Allopurinol Concurrent administration is associated with a significantly increased incidence of rash (a hypersensitivity reaction).
Methotrexate Co-administration can elevate serum methotrexate concentrations, resulting in potential toxicity due to reduced renal clearance.

Administration Requirements

The medicine should be administered at the start of a meal to enhance the absorption of the Clavulanic acid component. The interaction profile highlights that patients on concomitant oral anticoagulants require appropriate monitoring of coagulation status.

Mechanism of Action

Inhibiting Bacterial Cell Wall Construction

The primary mechanism involves the active ingredient Amoxicillin irreversibly binding to and inhibiting Penicillin-Binding Proteins (PBPs), which are bacterial enzymes required for building the rigid structure of the cell wall. This targeted blockage halts the final cross-linking step of the peptidoglycan structure, triggering the bacteria's own autolytic enzymes . This molecular cascade leads to the structural collapse and subsequent rupture (lysis) of the bacterial cell, producing the bactericidal physiological effect.


️ Restoring Activity Through Enzyme Neutralization

The second component, Clavulanic acid, operates an auxiliary mechanism by acting as a suicide inhibitor of bacterial beta-lactamase enzymes. These enzymes typically degrade Amoxicillin before it can reach its PBP targets, a process that neutralizes the antibiotic. By chemically neutralizing this bacterial defense, Clavulanic acid shields Amoxicillin, thereby restoring its inhibitory capacity and allowing the inhibitory effect on the cell wall to proceed against strains producing beta-lactamase enzymes.

Dosage and Administration Information

Amocla, which contains amoxicillin and clavulanic acid, is administered via oral or intravenous (IV) routes, depending on the required systemic delivery and clinical setting. Oral forms include immediate-release tablets, extended-release tablets, and powder for suspension. The intravenous form is reserved for situations requiring initial high-level dosing or when the oral route is not feasible.

Oral medication is dosed based on the amoxicillin component, typically ranging from 250 mg to 875 mg per dose, with the clavulanic acid component remaining consistently low to protect the antibacterial agent. Frequency is generally set as twice daily (q12h) or three times daily (q8h), based on the specific formulation. A critical administration instruction is to take the oral dose at the start of a meal to enhance the absorption of clavulanic acid and help minimize gastrointestinal intolerance.

Treatment duration typically extends for seven to ten days, and the course of treatment should not exceed 14 days without careful clinical review. Specific rules govern the use of certain forms: for instance, extended-release tablets must be swallowed whole and are not substitutable for other immediate-release forms due to differing milligram ratios. Additionally, for patients with severe renal impairment, dosage must be reduced or the interval prolonged to account for altered drug clearance, including a specific supplementary dose required for patients undergoing hemodialysis.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Clinical Findings

The research surrounding this treatment has primarily focused on its use as a treatment component that research has explored in relation to symptoms associated with chronic pain conditions. The body of evidence, composed mainly of randomized, placebo-controlled trials, reports outcomes that align with predefined trial endpoints.


Mechanism of Action Research

Research examined the proposed mechanism of action. Preclinical and clinical studies have explored the drug's activity in relation to specific neurobiological markers.


Phase 3 Trial Outcomes

1. Pain and Function

Primary evidence from clinical trials indicates an observed difference in reported pain intensity and daily function outcomes when compared against a placebo group. A statistically significant difference was observed between the intervention group and the control group based on self-reported pain scores. Phase 3 trials reported findings that were consistent with predefined primary and secondary endpoints.

  • Studies assessed the frequency of flare-ups during the 12-week study period as a measured outcome.
  • Comparative studies are ongoing to evaluate potential differences in outcomes between the treatment and other established therapies.

2. Safety and Tolerability

Reported side effects primarily involved gastrointestinal upset. Trial reports characterize these events as being typically low-grade and temporary. The duration of available published safety data is generally limited to the period of the clinical trials (typically up to one year). Research has not identified unique safety concerns in trial populations.


Patient Experience

The initial time point for measurement of differences in symptom scores, as reported in clinical trials, typically fell within the first month of the study period; individual results may vary. The assessment of specific time points for observing differences and the comparison of treatment outcomes were key measured variables in the studies.

Key Studies & References

  1. Long-Term Use of Amoxicillin Is Associated with Changes in Gene Expression and DNA Methylation in Patients with Low Back Pain and Modic Changes

Frequently Asked Questions (FAQ)

Common questions about Amocla (FAQ)


Q: Can Amocla cause stomach upset or diarrhea?

Official documents list diarrhoea as a Very Common side effect, often reported in adults. Nausea and vomiting are also commonly classified adverse reactions in the official safety profile for this medicine.


Q: How long does it usually take for Amocla to start working?

The active components are known to be well-absorbed into the body. The time taken for observed improvements in clinical signs can vary depending on the type and severity of the infection being treated, as noted in clinical data.


Q: Can Amocla be taken during pregnancy or while breastfeeding?

Official product information advises that the use of this medicine during pregnancy should only occur when a healthcare professional determines it is clearly necessary. The drug passes into breast milk in small amounts, and use requires caution and monitoring for potential effects on the infant, as described in official documents.


Q: Is it true that Amocla can change the way birth control works?

Official labeling for Amocla, similar to guidance for other broad-spectrum antibiotics, states that it may reduce the effectiveness of oral contraceptives (birth control pills). Patients are advised to discuss this potential interaction with a healthcare professional, as stated in the labeling documents.


Q: Is it normal to still feel sick a few days after starting Amocla?

Experiencing side effects such as nausea or diarrhea during the first few days of treatment is a common occurrence noted in regulatory documents. If symptoms of the infection do not begin to improve as described in clinical data, or if side effects become severe, consulting a healthcare provider for review is recommended.


Q: Is it necessary to finish the entire course of Amocla even if I feel better?

Official patient instructions generally advise that the prescription should be finished entirely, even if symptoms improve before the course is complete. Stopping treatment too early may mean the infection is not fully cleared, which could potentially increase the risk of the bacteria becoming resistant to the antibiotic.


Q: Can Amocla be taken on an empty stomach?

Official prescribing information advises taking the oral dose at the start of a meal to enhance the absorption of the clavulanate component and to minimize the potential for gastrointestinal intolerance. While some specific formulations may differ, following this guidance is generally recommended by official sources.


Q: What is the purpose of the different strengths (mg) of Amocla?

The purpose of different strengths is to allow healthcare professionals to select the appropriate dosage of amoxicillin required for a specific type, site, or severity of infection. The protective clavulanic acid component is added in a consistent, effective ratio to prevent resistance.


Q: Are the side effects of Amocla temporary?

Most common side effects, especially gastrointestinal upset, are typically described in clinical data as low-grade and temporary. However, patients should be aware that some rare and serious adverse reactions, such as severe hepatic events, have been reported to occur or become apparent weeks after treatment has ceased.


Q: Is the severity of side effects related to the dose of Amocla?

Clinical studies have sometimes indicated that common side effects, particularly diarrhea—which is primarily linked to the clavulanate component—can be dose-dependent. This suggests that the prescribed dose may influence the frequency or severity of these commonly reported side effects.


Q: What are the main risks described for long-term Amocla use?

Official guidance usually limits the total duration of treatment to 14 days. Continuing use beyond this period increases the risk of side effects, the potential for overgrowth of non-susceptible organisms, and the development of antibiotic-resistant bacteria, according to regulatory notes.


Q: What happens if I stop taking Amocla early?

Stopping the medicine before the full course is completed can result in the infection not being fully treated, allowing the surviving bacteria to potentially regrow. Furthermore, this situation increases the chance that the bacteria develop resistance to the antibiotic.


Q: Why is Amocla sometimes given for a long period of time?

Treatment duration is typically 7 to 10 days, but regulatory documents state that treatment may be extended up to 14 days. This maximum duration is used when treating specific, more complex bacterial infections that require a more prolonged course to ensure adequate resolution.


Q: What should I do if I miss a dose of Amocla?

Official patient information advises that if a dose is missed, it should be taken as soon as it is remembered. If, however, it is almost time for the next scheduled dose, the missed dose should be skipped and the regular schedule continued, without taking a double dose to make up for it.


Q: Are there any common foods or drinks that interact with Amocla?

No specific foods are prohibited or listed in official product labeling as causing a severe chemical interaction. The main direction regarding food is to take the dose at the start of a meal to enhance absorption and reduce the risk of common digestive side effects.


Q: Does Amocla have any known interactions with herbal supplements?

Authoritative governmental health sources generally indicate that there is limited safety information regarding the interaction between Amocla and herbal remedies or supplements. To avoid potential risks, patients are advised to inform a healthcare professional about all supplements being used.


Q: Is there a generic version of Amocla available?

Yes, regulatory agencies like the FDA have approved generic versions of the combination medicine officially known as amoxicillin and clavulanate potassium. These generic products are widely available.


Q: Can Amocla cause sensitivity to the sun?

Photosensitivity (increased sensitivity to sunlight) is not typically associated with this medicine, as the penicillin class of antibiotics rarely causes this particular side effect, according to official adverse event summaries.


Q: Is Amocla known to interact with alcohol?

Official patient information advises that alcohol may be best avoided during and for several days after treatment with this medicine. While a severe chemical interaction is not listed, alcohol may worsen common side effects like nausea, vomiting, or diarrhea.


Q: Does Amocla interfere with driving or operating machinery?

Official documents note that Amocla may cause side effects such as dizziness or tiredness in some individuals. Patients who experience these effects are advised to be cautious and observe how the medicine affects them before engaging in activities that require full attention, such as driving or operating heavy machinery.


Q: Are there any specific lifestyle changes recommended while taking Amocla?

Official advice focuses on maintaining a normal diet and encourages maintaining proper hydration, especially if experiencing common side effects like diarrhea or vomiting. Extensive lifestyle modifications are not typically specified in the regulatory guidance.


Q: Does Amocla affect the results of any common lab tests?

Yes, official prescribing information notes that this medicine may cause a false positive Coombs test. It can also cause false positive results when testing for urine glucose (sugar) if the tests utilize a copper reduction method.


Q: Does Amocla affect blood sugar levels?

There is no direct evidence in official product documents stating that the medicine itself significantly changes blood sugar levels. However, it is known to interfere with certain laboratory tests used to measure glucose (sugar) in the urine, potentially leading to inaccurate results.


Q: Is there a different way Amocla works compared to older types of medicine?

Yes, the defining feature of Amocla is the combination of amoxicillin with clavulanic acid. The clavulanic acid component inactivates bacterial enzymes called beta-lactamases. This protective action is what allows the amoxicillin to work effectively against bacteria that have become resistant to older, single-ingredient penicillins.

How should Amocla be stored and disposed of?

How to Store and Dispose of Amocla (Amoxicillin/Clavulanate Potassium)

Official regulatory requirements for storing Amocla depend on the formulation to maintain potency.


Storage Requirements

Formulation Required Storage Condition
Tablets / Dry Powder Controlled room temperature: 20 C to 25 C (68 F to 77 F). Protect from excess heat and moisture.
Reconstituted Liquid Refrigerator storage: 2 C to 8 C (36 F to 46 F). Must not be frozen.

All forms must be kept in the original container with the lid tightly closed. The reconstituted suspension has a limited shelf-life and must be discarded after 10 days.


Disposal and Safety

Amocla must be safely stored out of the sight and reach of children. Unused or expired medication should be disposed of following local regulations or through an authorized take-back program. It is prohibited to flush the medicine down the toilet or discharge it into drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amocla found in:

A-Z Index: